Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Volume 23 Issue 7, July 2005

'The Creation of Organs' depicts the potential to create organs and tissues from stem cells. This issue includes a focus on cell therapies for regenerative medicine. Painting by Hunter O'Reilly, Loyola University, Chicago

Volume 23 Issue 7

Subscribe

Editorial

Top of page ⤴

News

  • With follow-on biologics in the United States still stuck in regulatory purgatory, Israeli genericsgiant Teva Pharmaceuticals is forging ahead in biogenerics through a Chinese acquisition.

    • Alla Katsnelson
    News

  • Ambitious plans by the European Commission (EC) to double research spending during 2007–2013 were quietly shelved during the run-up to a political summit of EU heads of state on June 15–16.

    • Cormac Sheridan
    News

  • The clinical trials market is opening up in China. The most recent evidence has been provided by the opening of the Danish Centre for Clinical and Basic Research (CCBR) in Beijing

    • Hepeng Jia
    News

  • As two diagnostics companies learned recently at their expense, the FDA is taking a hard look at gene and protein expression–based tests.

    • Malorye A. Branca
    News
Top of page ⤴

News in Brief

Top of page ⤴

News

  • Conventional wisdom is that biotech floatations in Europe belong on the London stock market. But the CEO of the Swiss stock exchange is bullish about the advantages of his exchange for life science ventures.

    • Sabine Louët
    News
Top of page ⤴

Data Page

Top of page ⤴

News Feature

  • Against long odds, conventional wisdom and politics, efforts to commercialize stem cell research are underway and show signs of intelligent life. Stephan Herrera investigates.

    • Stephan Herrera
    News Feature
Top of page ⤴

Correspondence

Top of page ⤴

Commentary

Top of page ⤴

Investors Lab

Top of page ⤴

Feature

  • Biotech companies with business models as diverse as the products they are developing are laboring to move cell-based therapies into the clinic. Without a commercial success, however, investors will remain on the sidelines.

    • Ken Howard Wilan
    • Christopher Thomas Scott
    • Stephan Herrera
    Feature
Top of page ⤴

Patents

Top of page ⤴

News & Views

  • The creation in vitro of vascularized skeletal muscle represents a first step to the engineering of more complex tissue architectures.

    • Rakesh K Jain
    • Patrick Au
    • Dai Fukumura
    News & Views

  • The genome sequence of Pseudomonas fluorescens Pf-5 provides new insight into how this bacterium protects its plant host.

    • Dieter Haas
    News & Views

  • Plant antioxidant phytonutrients produced by the terpenoid and phenylpropanoid pathways have been increased simultaneously for the first time, creating an extra-nutritious tomato.

    • Richard A Dixon
    News & Views

  • Korean scientists have generated patient-specific embryonic stem cells, providing a novel tool for disease research and accelerating prospects for therapeutic applications.

    • George Q Daley
    News & Views
Top of page ⤴

Commentary

Top of page ⤴

Analysis

Top of page ⤴

Review Article

Top of page ⤴

Article

Top of page ⤴

Letter

Top of page ⤴

Erratum

Top of page ⤴

Corrigendum

Top of page ⤴

New on the Market

Top of page ⤴

Careers and Recruitment

Top of page ⤴

People

Top of page ⤴

Focus

  • A focus examining the scientific, legal, regulatory, and commercial context of current cell research for regenerative medicine.

    Focus
Top of page ⤴

Search

Advanced search

Quick links